238 related articles for article (PubMed ID: 18667037)
1. Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds.
Maki K; Matsumoto S; Watabe E; Iguchi Y; Tomishima M; Ohki H; Yamada A; Ikeda F; Tawara S; Mutoh S
Microbiol Immunol; 2008 Aug; 52(8):383-91. PubMed ID: 18667037
[TBL] [Abstract][Full Text] [Related]
2. FR209602 and related compounds, novel antifungal lipopeptides from coleophoma crateriformis no. 738. II. In vitro and in vivo antifungal activity.
Kanasaki R; Abe F; Furukawa S; Yoshikawa K; Fujie A; Hino M; Hashimoto S; Hori Y
J Antibiot (Tokyo); 2006 Mar; 59(3):145-8. PubMed ID: 16724454
[TBL] [Abstract][Full Text] [Related]
3. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.
Laverdière M; Lalonde RG; Baril JG; Sheppard DC; Park S; Perlin DS
J Antimicrob Chemother; 2006 Apr; 57(4):705-8. PubMed ID: 16464893
[TBL] [Abstract][Full Text] [Related]
4. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
5. Micafungin: a new echinocandin antifungal.
Joseph JM; Jain R; Danziger LH
Pharmacotherapy; 2007 Jan; 27(1):53-67. PubMed ID: 17192162
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis.
Spreghini E; Orlando F; Tavanti A; Senesi S; Giannini D; Manso E; Barchiesi F
J Antimicrob Chemother; 2012 Sep; 67(9):2195-202. PubMed ID: 22635526
[TBL] [Abstract][Full Text] [Related]
7. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
9. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth.
Cateau E; Rodier MH; Imbert C
J Antimicrob Chemother; 2008 Jul; 62(1):153-5. PubMed ID: 18407917
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice.
Najvar LK; Bocanegra R; Wiederhold NP; Lambros C; Najarian N; Patterson TF; Graybill JR
Clin Microbiol Infect; 2008 Jun; 14(6):595-600. PubMed ID: 18397335
[TBL] [Abstract][Full Text] [Related]
11. Serum differentially alters the antifungal properties of echinocandin drugs.
Paderu P; Garcia-Effron G; Balashov S; Delmas G; Park S; Perlin DS
Antimicrob Agents Chemother; 2007 Jun; 51(6):2253-6. PubMed ID: 17420211
[TBL] [Abstract][Full Text] [Related]
12. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
Jacobsen MD; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
Oliveira ER; Fothergill A; Kirkpatrick WR; Patterson TF; Redding SW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Apr; 105(4):457-9. PubMed ID: 18329581
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of disc diffusion and microdilution methods in susceptibility testing of micafungin against Candida species.
Ramírez M; Serrano MC; Castro C; López E; Almeida C; Fernández A; Romero A; Martín-Mazuelos E
J Antimicrob Chemother; 2006 Oct; 58(4):861-3. PubMed ID: 16916868
[TBL] [Abstract][Full Text] [Related]
15. Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis.
Mochizuki K; Suemori S; Udo K; Komori S; Ohkusu K; Yamada N; Ogura S
J Ocul Pharmacol Ther; 2011 Oct; 27(5):531-3. PubMed ID: 21751880
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis.
Ghannoum MA; Kim HG; Long L
J Antimicrob Chemother; 2007 Mar; 59(3):556-9. PubMed ID: 17242032
[TBL] [Abstract][Full Text] [Related]
17. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of micafungin against deep-seated candidiasis in cyclophosphamide-induced immunosuppressed mice.
Ninomiya M; Mikamo H; Tanaka K; Watanabe K; Tamaya T
J Antimicrob Chemother; 2005 Apr; 55(4):587-90. PubMed ID: 15728144
[TBL] [Abstract][Full Text] [Related]
19. Echinocandin pharmacodynamics: review and clinical implications.
Pound MW; Townsend ML; Drew RH
J Antimicrob Chemother; 2010 Jun; 65(6):1108-18. PubMed ID: 20335190
[TBL] [Abstract][Full Text] [Related]
20. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species.
Zeidler U; Bougnoux ME; Lupan A; Helynck O; Doyen A; Garcia Z; Sertour N; Clavaud C; Munier-Lehmann H; Saveanu C; d'Enfert C
J Antimicrob Chemother; 2013 Jun; 68(6):1285-96. PubMed ID: 23378416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
